📰 Concomitant Use News
Concomitant Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Concomitant Use. Real-time updates on events, politics, business and more.
May 31, 2024
An unprecedented 60% of patients remain alive without disease progression after five years Updated results show continued 81% reduction in risk of progression or death and 94% reduction in...
March 25, 2024
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport
March 11, 2024
Commercial launch of INPEFA® continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of...
November 12, 2023
(2023-11-12 | NDAQ:LXRX) INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
November 12, 2023
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) ...
November 12, 2023
Oral presentation delivered at the American Heart Association Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in...
November 1, 2023
As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved...
October 31, 2023
Median time to return to full baseline function occurred within 90 minutes following outpatient treatment with NAYZILAM® (midazolam) nasal spray, with a...
October 31, 2023
Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 -- Lexicon...
October 11, 2023
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart failure Abstracts published in the Journal of Managed Care &